The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men

Hormone Research

Volumn 60, Issue SUPPL. 1, 2003, Pages 121-124

  Harman, S Mitchell ^a,c   Blackman, Marc R ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Kronos Longevity Research Institute   (United States)

Author keywords

Adverse events; Elderly population; Fat mass; Growth hormone; Lean body mass; Oestrogen; Sex hormones; Testosterone

Indexed keywords

RECOMBINANT GROWTH HORMONE; SEX HORMONE;

AGED; AGING; ARTHRALGIA; BODY FAT; CANCER RISK; CARDIOVASCULAR PERFORMANCE; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; EDEMA; ENDURANCE; FEMALE; GLUCOSE INTOLERANCE; HORMONE ACTION; HUMAN; HUMAN EXPERIMENT; LEAN BODY WEIGHT; MALE; MOLECULAR INTERACTION; MUSCLE STRENGTH; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE;

ADIPOSE TISSUE; AGED; BODY COMPOSITION; BODY WEIGHT; CARDIOVASCULAR SYSTEM; DOUBLE-BLIND METHOD; FEMALE; GONADAL STEROID HORMONES; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MUSCLE, SKELETAL; PAIN; PHYSICAL ENDURANCE; TESTOSTERONE;

EID: 0041411599     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071236     Document Type: Conference Paper

References (16)

1. Corpas E, Harman SM, Blackman MR: Human growth hormone and human aging. Endocr Rev 1993;14:20-39.
2. Miller MM, Franklin KB: Theoretical basis for the benefit of postmenopausal estrogen substitution. Exp Gerontol 1999;34:587-604.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-731.
4. Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ: Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab 2002;283:E284-E294.
5. Riggs BL, Melton LJ 3rd: Involutional osteoporosis. N Engl J Med 1986;314:1676-1686.
6. Shimokata H, Andres R, Coon PJ, Elahi D, Muller DC, Tobin JD: Studies in the distribution of body fat. II. Longitudinal effects of change in weight. Int J Obes 1989;13:455-464.
7. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA: Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996;81:2865-2873.
8. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson B-A: Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997;82:2877-2884.
9. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
10. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ, Hintz RL, Sherman BM: Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990;70:519-527.
11. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R: Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470-479.
12. Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D: Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) 1993;39:417-425.
13. Chipman JJ, Attanasio AF, Birkett MA, Bates PC, Webb S, Lamberts SW: The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 1997;46:473-481.
14. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P, Wuster C: GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 1999;50:703-713.
15. Holly JM, Gunnell DJ, Davey Smith G: Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol 1999;162:321-330.
16. Rossouw JE, Anderson GL, Prentice RL, La-Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Morley KJ, Ockene J, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.